Caris Life Sciences (CAI) Other Operating Expenses (2024 - 2026)

Caris Life Sciences has reported Other Operating Expenses for 3 years, with the latest figure at $116.5 million in Q2 2026.

• On a quarterly basis, Other Operating Expenses rose 25.56% year-over-year to $116.5 million in Q2 2026; TTM through Jun 2026 was $417.4 million, a 18.96% increase from a year earlier, with the FY2025 full-year figure at $374.4 million, up 7.79% from the prior year.
• Other Operating Expenses was $116.5 million for Q2 2026 at Caris Life Sciences, up from $106.1 million in the prior quarter.
• The five-year high for Other Operating Expenses was $116.5 million in Q2 2026, with the low at $84.9 million in Q3 2024.
• Average Other Operating Expenses over 3 years is $95.1 million, with a median of $91.0 million recorded in 2025.
• The sharpest annual moves came in 2025 and 2026: Other Operating Expenses climbed 6.28% in 2025, then increased 25.56% in 2026.
• Over 3 years, Other Operating Expenses stood at $86.3 million in 2024, then gained by 20.27% to $103.8 million in 2025, then gained by 12.19% to $116.5 million in 2026.
• The last three Other Operating Expenses figures came in at $116.5 million (Q2 2026), $106.1 million (Q1 2026), and $103.8 million (Q4 2025), per Business Quant data.